Lipocine (NASDAQ:LPCN) Releases Earnings Results, Beats Expectations By $0.31 EPS

Lipocine (NASDAQ:LPCN) issued its quarterly earnings results on Thursday. The specialty pharmaceutical company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.31, Zacks reports. The company had revenue of $2.29 million during the quarter, compared to analyst estimates of $0.16 million. Lipocine had a negative net margin of 755.39% and a negative return on equity of 64.75%.

Lipocine Trading Up 2.6%

Shares of NASDAQ:LPCN traded up $0.04 during midday trading on Friday, reaching $1.57. The company had a trading volume of 507,960 shares, compared to its average volume of 5,694,962. The company has a fifty day simple moving average of $1.92 and a two-hundred day simple moving average of $3.77. Lipocine has a 1-year low of $1.36 and a 1-year high of $12.37.

Insider Buying and Selling

In other news, Director John Higuchi acquired 15,970 shares of Lipocine stock in a transaction on Wednesday, September 30th. The stock was bought at an average cost of $2.23 per share, with a total value of $35,613.10. Following the completion of the purchase, the director owned 241,365 shares of the company’s stock, valued at $538,243.95. This represents a 7.09% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have bought 37,568 shares of company stock worth $82,174 over the last ninety days. 4.69% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

LPCN has been the subject of several research analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of Lipocine in a report on Tuesday, September 22nd. Weiss Ratings upgraded shares of Lipocine from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, October 29th. HC Wainwright reiterated a “neutral” rating and issued a $4.00 price target on shares of Lipocine in a research report on Monday, September 21st. Finally, Wall Street Zen raised shares of Lipocine from a “sell” rating to a “hold” rating in a report on Saturday, July 18th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $4.00.

Lipocine Company Profile

Lipocine Inc is a biopharmaceutical company focused on developing oral therapies for conditions with significant unmet medical needs. The company uses its proprietary Lip’ral drug-delivery technology to improve the absorption and clinical performance of active pharmaceutical ingredients that may otherwise have limited effectiveness when taken orally.

Lipocine’s lead product is Tlando, an oral testosterone replacement therapy containing testosterone undecanoate. The U.S. Food and Drug Administration approved Tlando in 2022 for testosterone replacement therapy in adult males with hypogonadism associated with an underlying medical condition.